Abstract 350P
Background
Currently, various chemotherapy regimens have been reported for the efficacy of unresectable squamous cell carcinoma (cSCC). However, there is no clear consensus. Here, we report the treatment results of unresectable cSCC in which concurrent chemoradiotherapy (CCRT) combining low-dose cisplatin and 5-fluorouracil (low-dose FP therapy) was performed in our department.
Methods
A two-year retrospective study was conducted for 23 patients who had been received CCRT with low-dose FP therapy for unresectable cSCC. The patient age ranged from 44 to 79 years (mean age, 71 years), and gender was 17 men and 6 women. The primary lesions of unresectable cSCC were present in 7 cases in the head and neck, in 1 case in the upper limbs, in 5 cases in the lower limbs, and in 10 cases in the perineal region. Radiotherapy (RT) of CCRT had irradiated the primary lesion and regional lymph nodes. And for chemotherapy of CCRT, low-dose FP therapy was used.
Results
When 23 patients were classified by TNM staging (UICC 8th), stage 3 of unresectable cSCC was 5 patients (21.7%) and stage 4 was 18 patients (78.3%). 6 cases who those with stage 4 were dead (26.1%), while there were no dead cases who those with stage 3. Overall response rate (ORR) was 81 %, and median progression-free survival (PFS) was 392 days. For stage 4 of unresectable cSCC, one-year overall survival (OS) was 78 %, two-year OS was 56.7%, median survival time (MST) was 560 days.
Conclusions
CCRT with low-dose FP therapy is an effective treatment for unresectable cSCC. However, tumors of the primary lesion and / or regional lymph nodes may remain after CCRT. In such cases, chemotherapy (i.e., maintenance therapy [MT]) should be continued after CCRT. In our department, most cases of unresectable cSCC receive MT after CCRT. Therefore, in the first treatment of unresectable cSCC, it is important how to make the tumor smaller. In this study, our cases had optimal results of ORR, median PFS, OS, and MST. According to these facts and results, we considered CCRT with low-dose FP therapy suppressed cSCC and is an effective treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
87P - Negative to positive lymph node ratio-prognostic marker of survival in node positive rectal cancer
Presenter: Pavan Jonnada
Session: Poster display session
Resources:
Abstract
88P - The Sidra LUMC advanced colon cancer NGS cohort
Presenter: Wouter Hendrickx
Session: Poster display session
Resources:
Abstract
89P - A phase II trial of adjuvant chemoradiotherapy for patients with high-risk rectal submucosal invasive cancer after local resection
Presenter: Masaaki Noguchi
Session: Poster display session
Resources:
Abstract
90P - High MICB expression confers prognostic benefit in colorectal cancer
Presenter: Shanchao Yu
Session: Poster display session
Resources:
Abstract
91P - Adjuvant therapy for high-risk stage II or stage III colon adenocarcinoma: A propensity score-matched, nationwide, population-based cohort study
Presenter: Chien-Hsin Chen
Session: Poster display session
Resources:
Abstract
92P - Prospective randomized controlled study comparing primary surgery versus neoadjuvant chemotherapy followed by surgery in gastric carcinoma
Presenter: Vipin Goel
Session: Poster display session
Resources:
Abstract
93P - Biomarker selection of liver metastatic colorectal patients for anti-EGFR monoclonal antibodies: A machine learning analysis
Presenter: Yijiao Chen
Session: Poster display session
Resources:
Abstract
94P - NORTH/HGCSG1003: North Japan multicenter phase II study of oxaliplatin-containing regimen as adjuvant chemotherapy for stage III colon cancer: Final analysis
Presenter: Michio Nakamura
Session: Poster display session
Resources:
Abstract
95P - Anatomical resections improve relapse-free survival in patients with KRAS/NRAS/BRAF- mutated colorectal liver metastases
Presenter: Ye Wei
Session: Poster display session
Resources:
Abstract
96P - Incidence, characteristics and prognosis in colorectal cancer with CNS metastases
Presenter: Nicola Taylor
Session: Poster display session
Resources:
Abstract